Search research articles
Contact Us
Filters
Showing results (21-30 of 52) with videos related to
Page
of 6
Sort By:
American Journal of Physiology. Lung Cellular and Molecular Physiology
|
February 5, 2013
Loss of Cftr function exacerbates the phenotype of Na(+) hyperabsorption in murine airways
Alessandra Livraghi-Butrico, Elizabeth J Kelly, Kristen J Wilkinson, et al.
Microbiology Spectrum
|
March 6, 2023
Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants
Tiffany L Roe, Tyler Brady, Nicolette Schuko, et al.
Vaccine
|
September 6, 2024
Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY)
Kevin M Tuffy, Bahar Ahani, Joseph B Domachowske, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 30, 2021
T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire
Phillip A Swanson, Marcelino Padilla, Wesley Hoyland, et al.
Science Translational Medicine
|
September 30, 2021
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T<sub>H</sub>1 response with a diverse TCR repertoire
Phillip A Swanson, Marcelino Padilla, Wesley Hoyland, et al.
Microbiology Spectrum
|
August 22, 2022
Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring
Tyler Brady, Tianhui Zhang, Kevin M Tuffy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 10, 2024
Lower respiratory tract infections following respiratory syncytial virus monoclonal antibody nirsevimab immunization versus placebo: Analysis from a Phase 3 randomized clinical trial (MELODY)
Doug Arbetter, Vancheswaran Gopalakrishnan, Anastasia A Aksyuk, et al.
The Journal of Infectious Diseases
|
June 6, 2023
Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants
Kevin M Tuffy, Bahar Ahani, Anastasia A Aksyuk, et al.
Infectious Diseases and Therapy
|
November 2, 2023
Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)
Gustavo H Kijak, Bahar Ahani, Douglas Arbetter, et al.
The New England Journal of Medicine
|
April 5, 2023
Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants
William J Muller, Shabir A Madhi, Beatriz Seoane Nuñez, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 52) with videos related to
Sort By:
Page
of 6
American Journal of Physiology. Lung Cellular and Molecular Physiology
|
February 5, 2013
Loss of Cftr function exacerbates the phenotype of Na(+) hyperabsorption in murine airways
Alessandra Livraghi-Butrico, Elizabeth J Kelly, Kristen J Wilkinson, et al.
Microbiology Spectrum
|
March 6, 2023
Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants
Tiffany L Roe, Tyler Brady, Nicolette Schuko, et al.
Vaccine
|
September 6, 2024
Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY)
Kevin M Tuffy, Bahar Ahani, Joseph B Domachowske, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 30, 2021
T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire
Phillip A Swanson, Marcelino Padilla, Wesley Hoyland, et al.
Science Translational Medicine
|
September 30, 2021
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T<sub>H</sub>1 response with a diverse TCR repertoire
Phillip A Swanson, Marcelino Padilla, Wesley Hoyland, et al.
Microbiology Spectrum
|
August 22, 2022
Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring
Tyler Brady, Tianhui Zhang, Kevin M Tuffy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 10, 2024
Lower respiratory tract infections following respiratory syncytial virus monoclonal antibody nirsevimab immunization versus placebo: Analysis from a Phase 3 randomized clinical trial (MELODY)
Doug Arbetter, Vancheswaran Gopalakrishnan, Anastasia A Aksyuk, et al.
The Journal of Infectious Diseases
|
June 6, 2023
Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants
Kevin M Tuffy, Bahar Ahani, Anastasia A Aksyuk, et al.
Infectious Diseases and Therapy
|
November 2, 2023
Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)
Gustavo H Kijak, Bahar Ahani, Douglas Arbetter, et al.
The New England Journal of Medicine
|
April 5, 2023
Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants
William J Muller, Shabir A Madhi, Beatriz Seoane Nuñez, et al.
Page
of 6